Concizumab in patients with Hemophilia A/B: a systematic review
DOI:
https://doi.org/10.35434/rcmhnaaa.2022.15Supl.%201.1539Keywords:
Concizumab, Hemophilia, Systematic reviewAbstract
Objective: We systematically assessed the efficacy of Concizumab in patients with Hemophilia A/B. Material and Methods: Five databases were searched up to May 2022 for randomized controlled trials in adults with severe Hemophilia A/B with or without inhibitors treated with Concizumab compared to standard care or placebo. Outcomes were bleeding episodes (ABRs), D - dimer, prothrombin fragment 1.2, fibrinogen levels, prothrombin time, nasopharyngitis, and upper respiratory tract infection. Results: Two RCTs (n = 86) were included. In both studies, decreased bleeding rates were observed at high levels of concizumab. Furthermore, both studies support the use of concizumab as a safe and well-tolerated prophylactic therapy administered subcutaneously in all haemophilia patients. Placebo was the comparator in one RCT, while Eptacog alfa (activated) rFVIIIa was the comparator in the other RCT. The dosing of concizumab in the RCTs ranged from 0.15, 0.20, 0.25, 0.5 and 0.8, mg/kg with follow-up times between 42 days and 24 weeks. Conclusion: The efficacy and safety of Concizumab for the treatment of patients with Hemophilia A/B cannot be estimated or recommended due to the weak evidence and low number of relevant studies supporting its use.
Downloads
Metrics
References
Morfini M, Zanon E. Emerging drugs for the treatment of hemophilia A and B. Expert Opinion on Emerging Drugs. 2016;21(3):301-13. doi:10.1080/14728214.2016.1220536.
Teitel JM. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors. Transfus Apheresis Sci. 2018;57(4):466-71. doi:10.1016/j.transci.2018.07.011.
Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jimenez-Yuste V, et al. Evaluation of safety and establishment of a PK/PD relationship of concizumab in hemophilia a patients. Research and practice in thrombosis and haemostasis. 2017;1:1‐2.
Valentino LA, Khair K. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations. Expert Review of Hematology. 2020;13(7):731-43. doi:10.1080/17474086.2020.1775576.
Shapiro AD, Castaman G, Cepo K, Marie Tønder S, Matsushita T, Hvitfeldt Poulsen L, et al. Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Blood. 2020;136:40-1. doi:10.1182/blood-2020-139910.
Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jimenez-Yuste V, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184-95. doi:10.1111/jth.14272.
Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134(22):1973-82. doi:10.1182/blood.2019001542.
Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743-54. doi:10.1111/jth.12864.
Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, et al. Haemophilia. Nature Reviews Disease Primers. 2021;7(1):45. doi:10.1038/s41572-021-00278-x.
Lauritzen B, Hilden I. Concizumab promotes haemostasis via a tissue factor-factor VIIa-dependent mechanism supporting prophylactic treatment of haemophilia: Results from a rabbit haemophilia bleeding model. Haemophilia. 2019;25(6):e379-e82. doi:10.1111/hae.13861.
Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017;23(5):769-76. doi:10.1111/hae.13260.
Agerso H, Overgaard RV, Petersen MB, Hansen L, Hermit MB, Sorensen MH, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014;56:65-9. doi:10.1016/j.ejps.2014.02.009.
Okaygoun D, Oliveira DD, Soman S, Williams R. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci. 2021;28(1):64. doi:10.1186/s12929-021-00760-4.
Mahlangu J, Paz P, Hardtke M, Aswad F, Schroeder J. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016;22(6):873-9. doi:10.1111/hae.12994.
Male C, Andersson NG, Rafowicz A, Liesner R, Kurnik K, Fischer K, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2021;106(1):123-9. doi:10.3324/haematol.2019.239160.
Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. (1520-4383 (Electronic)).
Kjalke M, Kjelgaard-Hansen M, Andersen S, Hilden I. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021;19(7):1687-96. doi:10.1111/jth.15323.
Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jimenez-Yuste V, et al. Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data. Haemophilia. 2019;25(1):60-6. doi:10.1111/hae.13627.
Chowdary P. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. Drugs. 2018;78(9):881-90. doi:10.1007/s40265-018-0922-6.
Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134(22):1973-82. doi:10.1182/blood.201900154
C. Diaz-Arocutipa, J. K. Benites-Meza, D. Chambergo-Michilot, J. J. Barboza, V. Pasupuleti, H. Bueno, et al. Efficacy and Safety of Colchicine in Post-acute Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med. 2021 Vol. 8 Pages 676771. 10.3389/fcvm.2021.676771
J. J. Barboza, L. Albitres-Flores, M. Rivera-Meza, J. Rodriguez-Huapaya, J. Caballero-Alvarado, V. Pasupuleti, et al. Short-term efficacy of umbilical cord milking in preterm infants: systematic review and meta-analysis. Pediatr Res. 2021 Vol. 89 Issue 1 Pages 22-30. 10.1038/s41390-020-0902-x
J. J. Barboza, D. Chambergo-Michilot, M. Velasquez-Sotomayor, C. Silva-Rengifo, C. Diaz-Arocutipa, J. Caballero-Alvarado, et al. Assessment and management of asymptomatic COVID-19 infection: A systematic review. Travel Med Infect Dis. 2021 Vol. 41 Pages 102058. 10.1016/j.tmaid.2021.102058
A. V. Hernandez, J. Ingemi, 3rd, M. Sherman, V. Pasupuleti, J. J. Barboza, A. Piscoya, et al. Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2021 Vol. 10 Issue 12. https://doi.org.10.3390/jcm10122609
Toro-Huamanchumo CJ, Benites-Meza JK, Mamani-García CS, Bustamante-Paytan D, Gracia-Ramos AE, Diaz-Vélez C, Barboza JJ. Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2022; 11(9):2615. https://doi.org/10.3390/jcm11092615
Toro-Huamanchumo CJ, Hilario-Gomez MM, Diaz-Reyes N, Caballero-Alvarado JA, Barboza JJ. The Efficacy of CPAP in Neonates with Meconium Aspiration Syndrome: A Systematic Review and Meta-Analysis. Children. 2022; 9(5):589. https://doi.org/10.3390/children9050589
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Ana Valle-Chafloque, Karen Uchofén-Mondragón, Liseth Pinedo-Castillo, Carlos J. Zumarán-Núñez, Delia F. Dávila-Vigil, Joshuan J. Barboza
This work is licensed under a Creative Commons Attribution 4.0 International License.
